Morgan Stanley analyst Dara Mohsenian maintains Coca-Cola (NYSE:KO) with a Overweight and raises the price target from $68 to $70.
UBS Upgrades Alnylam Pharmaceuticals to Buy, Raises Price Target to $215
UBS analyst Esther Rajavelu upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Neutral to Buy and raises the price target from $141 to $215.